PR Newswire BiotechOriginal article
Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula
Data ReadoutpositiveTREMFYAPositive
AI Analysis
Summary
Johnson & Johnson announced new data showing TREMFYA (guselkumab) maintained combined fistula remission through Week 48 in Crohn's disease patients with perianal fistula across both maintenance dose regimens. In the 100 mg group, remission increased from 28% at Week 24 to 35% at Week 48.
Clinical Trial Data
Phase
Phase_3
Outcome Details
Combined fistula remission was maintained through Week 48 across both maintenance dose regimens, with an increase from 28% at Week 24 to 35% at Week 48 in the 100 mg dose group.
Importance:5/10
Sentiment:
0.60
Crohn's diseaseperianal fistulaIL-23guselkumabPhase 3immunologydurable remission48-week data
Related Companies
Read the original article
Published by PR Newswire Biotech on October 19, 2026 12:00 PM